- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Fabry disease
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 May 2024 May 2026 PBAC Meetings - (PDF 940KB)
- Public Summary Document (PSD) March 2024 May 2024 May 2026 PBAC Meetings - (Word 255KB)
Migalastat – March 2024 – May 2024
– May 2026
Migalastat: Capsule containing migalastat hydrochloride 150 mg; Galafold® – March 2024 – May 2026 PBAC meetings
Last updated
24 April 2026